NCT02936479View on ClinicalTrials.gov

C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection

PHASE2CompletedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

October 30, 2018

Study Completion Date

October 30, 2018

Conditions

Antibody Mediated Rejection of Kidney Transplant

Interventions

DRUG

C1-INH (Berinert)

Trial Locations (1)

10016

New York University School of Medicine, New York

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

CSL Behring

INDUSTRY

lead

NYU Langone Health

OTHER